PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…
Radicle Science studied MDSleep in one of history’s largest clinical trials on a supplement brand’s sleep formulation.Los Angeles, CA, Oct.…
Expands access to vertebrogenic pain treatment for 36 million patientsMINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company…
Cannabix Technologies Inc. Cannabix Technologies MSBS and BCU Figures 1 and 2 VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE)…
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent…
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company…
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose…
WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed…
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO…